Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.

Abstract

INTRODUCTION:

Recent studies have demonstrated that inactivated seasonal influenza vaccines (IIV) may elicit production of heterosubtypic antibodies, which can neutralize avian H5N1 virus in a small proportion of subjects. We hypothesized that prime boost regimens of live and inactivated trivalent seasonal influenza vaccines (LAIV and IIV) would enhance production of heterosubtypic immunity and provide evidence of cross-protection against other influenza viruses.

METHODS:

In an open-label study, 26 adult volunteers were randomized to receive one of four vaccine regimens containing two doses of 2009-10 seasonal influenza vaccines administered 8 (±1) weeks apart: 2 doses of LAIV; 2 doses of IIV; LAIV then IIV; IIV then LAIV. Humoral immunity assays for avian H5N1, 2009 pandemic H1N1 (pH1N1), and seasonal vaccine strains were performed on blood collected pre-vaccine and 2 and 4 weeks later. The percentage of cytokine-producing T-cells was compared with baseline 14 days after each dose.

RESULTS:

Subjects receiving IIV had prompt serological responses to vaccine strains. Two subjects receiving heterologous prime boost regimens had enhanced haemagglutination inhibition (HI) and neutralization (NT) titres against pH1N1, and one subject against avian H5N1; all three had pre-existing cross-reactive antibodies detected at baseline. Significantly elevated titres to H5N1 and pH1N1 by neuraminidase inhibition (NI) assay were observed following LAIV-IIV administration. Both vaccines elicited cross-reactive CD4+ T-cell responses to nucleoprotein of avian H5N1 and pH1N1. All regimens were safe and well tolerated.

CONCLUSION:

Neither homologous nor heterologous prime boost immunization enhanced serum HI and NT titres to 2009 pH1N1 or avian H5N1 compared to single dose vaccine. However heterologous prime-boost vaccination did lead to in vitro evidence of cross-reactivity by NI; the significance of this finding is unclear. These data support the strategy of administering single dose trivalent seasonal influenza vaccine at the outset of an influenza pandemic while a specific vaccine is being developed.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01044095.

• Authors: Delia Bethell, David Saunders, Anan Jongkaewwattana, Jarin Kramyu, Arunee Thitithayanont, Suwimon Wiboon-ut, Kosol Yongvanitchit, Amporn Limsalakpetch, Utaiwan Kum-Arb, Nichapat Uthaimongkol, Jean Michel Garcia, Ans E Timmermans, Malik Peiris, Stephen Thomas, Anneke Engering, Richard G Jarman, Duangrat Mongkolsirichaikul, Carl Mason, Nuanpan Khemnu, Stuart D Tyner, Mark M Fukuda, Douglas S Walsh, Sathit Pichyangkul
• Journal: PloS one (PLoS One) Vol. 8 Issue 3 Pg. e59674 ( 2013) ISSN: 1932-6203 [Electronic] United States
• PMID: 23555741 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Viral
• Viral Vaccines

Topics

• Adolescent
• Adult
• Animals
• Antibodies, Viral (blood, immunology)
• Birds
• Cross Reactions
• Feasibility Studies
• Female
• Health
• Humans
• Immunization, Secondary (adverse effects, methods)
• Influenza A Virus, H1N1 Subtype (immunology, physiology)
• Influenza A Virus, H5N1 Subtype (immunology, physiology)
• Influenza in Birds (immunology, prevention & control)
• Influenza, Human (epidemiology, immunology, prevention & control)
• Male
• Middle Aged
• Orthomyxoviridae (immunology, physiology)
• Pandemics (prevention & control)
• Pilot Projects
• Safety
• Seasons
• T-Lymphocytes (immunology, virology)
• Vaccination (adverse effects, methods)
• Viral Vaccines (adverse effects, immunology)
• Young Adult